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Background
Platelets are specialized anucleate cells that play key roles
in hemostasis through their ability to rapidly adhere to
subendothelial matrix proteins and endothelial cells
(platelet adhesion) and to other activated platelets (plate-
let aggregation). Platelet activation is an irreversible proc-
ess resulting ultimately in platelet apoptosis and death.
The NO-cGMP-PKG pathway plays an essential role in
platelet inhibition, however the role of this pathway in
regulation of platelet apoptosis has not been investigated
in detail so far. Surface exposure of negatively charged
phospholipid phosphatidylserine (Annexin V-binding)
and loss of mitochondrial membrane potential (ΔΨm) of
activated platelets were used as markers of platelet apop-
tosis induced by thrombin (up to 0.5 U/ml), convulxin
(Cvx 5 ng/ml) or by a mixture of thrombin/convulxin
(Thr/Cvx 0.005 U/ml/5 ng/ml).
Results
Thrombin alone, even at high concentrations, had no
effect on Annexin V-binding, Cvx alone (190 ± 12%), and
combination of Thr/Cvx (640 ± 60%) significantly
increased Annexin V binding (mean fluorescence) after 2
min of stimulation. An NO donor (DEA-NO,1 μM)
increased platelet cGMP content, induced vasodilator-
stimulated phosphoprotein (VASP) phosphorylation, and
significantly (48 ± 5%) inhibited Cvx-evoked Annexin V-
binding in platelets. The effect of DEA-NO was signifi-
cantly enhanced (up to 15%) by the PDE5 inhibitor silde-
nafil (5 μM) and attenuated by preincubation (5 min)
with the sGC inhibitor (ODQ, 5 μM). A membrane-per-
meable cGMP analog (8-pCPT-cGMP, 100 μM,10 min
preincubation) also induced VASP phosphorylation,
however, it only slightly (17 ± 3%) inhibited Cvx-
increased Annexin V-binding (all data calculated as %
inhibition with Annexin V-binding in the presence of Cvx
alone used 100%). When platelet apoptosis was induced
with stronger stimuli (Thr/Cvx) the inhibitory effects of
NO donors were less pronounced (20 ± 4%) when com-
pared to platelets stimulated with Cvx alone. In Thr/Cvx
stimulated platelets mitochondrial membrane potential
(ΔΨm) was reduced up to 40 ± 5% compared to the con-
trol, and this effect was significantly inhibited (61 ± 12%)
by DEA-NO (1 μM). However, in contrast to its effect on
Annexin V-binding (see above), the DEA-NO effects on
mitochondrial membrane potential (ΔΨm) were not
attenuated by ODQ which (as positive control) com-
pletely prevented DEA-NO induced cGMP increase and
VASP phosphorylation.
Conclusion
We conclude that NO inhibits platelet apoptosis by
cGMP-dependent (in the case of phosphatidylserine sur-
face exposure) and cGMP-independent (loss of mitochon-
drial membrane potential) mechanisms.
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